Physician profile
Anthony C Brown
NPI 1144486770
$21,818.25
in general payments reported to CMS, 2019-2025
71 companies · $4,013 in 2025
The $4,013 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $1,273 · 2021: $2,575 · 2022: $3,737 · 2023: $4,397 · 2024: $4,239 · 2025: $4,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $89.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,560.36 |
| Education | $89.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,385.19 | 2020-2025 | Qulipta, Ubrelvy, Duopa |
| Ucb, INC. | $1,667.07 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
| Lundbeck LLC | $1,430.80 | 2020-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $1,204.49 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $1,080.40 | 2019-2025 | Nuplazid, Daybue |
| Amgen INC. | $992.47 | 2019-2025 | Uplizna, Krystexxa |
| Ge Healthcare | $702.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $692.36 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $593.76 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $530.38 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $507.17 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Genentech USA, INC. | $487.95 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $447.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $429.90 | 2019-2025 | Amyvid, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $423.23 | 2022 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $405.35 | 2019-2025 | |
| Csl Behring | $375.27 | 2019-2025 | Hizentra |
| Pfizer INC. | $366.88 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $349.35 | 2020-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $347.13 | 2019-2024 | Vumerity, Tysabri |
| Neurelis, INC. | $314.95 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $301.70 | 2021-2025 | |
| Acorda Therapeutics, INC | $290.12 | 2019-2024 | Inbrija, Ampyra |
| Mdd US Operations, LLC | $288.78 | 2021-2025 | Gocovri, Gocovri, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $283.81 | 2022-2025 | Hyqvia |
| Amneal Pharmaceuticals LLC | $280.79 | 2020-2024 | Crexont, Rytary |
| Celgene Corporation | $267.65 | 2021-2025 | Zeposia |
| Eisai INC. | $266.75 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $249.41 | 2020-2021 | |
| Emd Serono, INC. | $235.38 | 2021-2025 | Mavenclad |
| Horizon Therapeutics Plc | $230.84 | 2022-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $216.14 | 2019-2023 | Onpattro |
| Revance Therapeutics, INC. | $200.77 | 2024 | Daxxify |
| Octapharma USA, INC. | $193.75 | 2022-2023 | Panzyga |
| Scilex Pharmaceuticals INC. | $186.21 | 2023-2025 | Ztlido |
| Upsher-Smith Laboratories LLC | $183.43 | 2021-2023 | |
| Catalyst Pharmaceuticals, INC. | $169.40 | 2020-2025 | Firdapse |
| Kyowa Kirin, INC. | $161.34 | 2021-2024 | Nourianz |
| Tg Therapeutics, INC. | $150.34 | 2024-2025 | |
| Grifols USA, LLC | $146.86 | 2020-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $131.69 | 2023-2025 | Nuedexta, Rexulti |
| Sunovion Pharmaceuticals INC. | $130.68 | 2020-2022 | |
| Avion Pharmaceuticals | $111.24 | 2021-2023 | Dhivy |
| Adamas Pharmaceuticals, INC. | $110.11 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $103.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $101.99 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.03 | 2020-2022 | |
| Almatica Pharma LLC | $87.07 | 2022-2023 | Gralise |
| Merz North America, INC. | $76.46 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $73.23 | 2024 | |
| Janssen Biotech, INC. | $69.95 | 2025 | |
| Hema Biologics, LLC | $65.88 | 2023 | Sevenfact |
| Corium, LLC | $47.46 | 2022-2023 | Adlarity |
| Livanova USA, INC. | $47.37 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Aprecia Pharmaceuticals, LLC | $42.17 | 2022 | |
| Medtronic, INC. | $41.93 | 2024 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $39.82 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $39.69 | 2022 | |
| Mallinckrodt Hospital Products INC. | $39.54 | 2021-2022 | |
| Tanabe Pharma America, INC. | $39.11 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $38.30 | 2023-2025 | Andexxa, Wainua |
| Impel Pharmaceuticals INC. | $36.56 | 2022-2023 | Trudhesa |
| Ipsen Biopharmaceuticals, INC | $34.42 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.13 | 2025 | Opsumit, Uptravi |
| Insightec,INC | $27.68 | 2023 | Exablate |
| Vanda Pharmaceuticals INC. | $26.58 | 2024 | Ponvory |
| Springworks Therapeutics, INC. | $24.95 | 2025 | Gomekli |
| Grt US Holding, INC. | $20.86 | 2022 | |
| C2n Diagnostics, LLC | $18.77 | 2025 | Precivityad2 |
| Sandoz INC. | $16.47 | 2023 | |
| Kedrion Biopharma, INC. | $14.08 | 2025 | Kedrab, Koate, Gammaked |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.